Stockscreener 앱 받기
13.14
1.72%
-0.23
시간 외 거래:
13.24
0.10
+0.76%
Tonix Pharmaceuticals Holding Corp 주식(TNXP)의 최신 뉴스
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26 - finance.yahoo.com
Tonix CEO will speak at a healthcare conference Sept. 10 - Stock Titan
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock - MarketBeat
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock - Investing.com
Tonix Pharma (NASDAQ: TNXP) CEO adds 2,000 shares in IRA - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Canada
Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) Director Purchases $12,600.00 in Stock - MarketBeat
Tonix (TNXP) Market: Adds 1.29% to Close at $12.55; the Near-Term Reference Band Stretches From $11.92 to $13.18 in the Latest ReadingPositive Gamma - siam.in
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript - AOL.com
Tonix (TNXP) Daily Snapshot: Finishes 0.16% Higher at $12.68 in Latest Trading; the $12.05 to $13.31 Range Remains in Focus under the Current SnapshotValue Area High - Vinanet
Why TNXP Stock Is Suddenly Back On Retail Radar - stocktwits.com
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline - MarketBeat
Tonix Pharmaceuticals (TNXP) Holds Ground at $12.66 as Traders Eye $13.29 ResistanceTrend Reversal Picks - vinanet.vn
Tonix Pharmaceuticals Holding Corp. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TNXP) 2026-08-14 - Seeking Alpha
Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants - Stock Titan
AQR Capital discloses 5.54% ownership in Tonix Pharmaceuticals (TNXP) via Schedule 13G - Stock Titan
TNXP Q2 2026 Earnings: Better-Than-Expected Loss per Share, Shares Dip 3%Guidance Accuracy Score - Vinanet
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Tonix Pharmaceuticals Holding Corp.Common Stock (NQ: TNXP - FinancialContent
Industry Analysts Just Made A Dazzling Upgrade To Their Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Revenue Forecasts - Moomoo
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance UK
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build By Investing.com - Investing.com UK
Tonix Pharmaceuticals (TNXP) Revenue Surge Meets Persistent Cash Burn Concerns - simplywall.st
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build - Investing.com India
Tonix Pharmaceuticals: TONMYA Refills Surge 207% As Coverage Reaches 136 Million U.S. Lives - Pulse 2.0
Tonix Pharma earnings beat by $0.27, revenue topped estimates - Investing.com Nigeria
Tonix Delivers A Beat, But The Real Test Starts Now (NASDAQ:TNXP) - Seeking Alpha
Raymond James raises Tonix Pharma stock price target on strong sales - Investing.com UK
Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal? - Kalkine Media
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Cal - GuruFocus
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ... - Yahoo Finance UK
Tonix Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Tonix Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
TNXP: Tonmya's launch fueled major Q2 revenue growth and pipeline progress, with cash runway into 2027 - TradingView
Earnings call transcript: Tonix beats Q2 2026 estimates as TONMYA sales surge - Investing.com Nigeria
Tonix Pharmaceuticals Holding Releases Q2 2026 Financial Results - AlphaStreet
TNXP: TONMYA sales nearly tripled in Q2 2026, driving revenue growth and supporting robust pipeline progress - TradingView
Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results - MarketBeat
TNXP: Q2 2026 net revenue reached $13.5M, driven by TONMYA's 197% QoQ sales growth - tradingview.com
Q2 2026 Tonix Pharmaceuticals Holding Corp Earnings Call Transcript - GuruFocus
Is Tonix Pharmaceuticals (TNXP) Overvalued After Q2 Earnings Rep - GuruFocus
TNXP Looks 584.3% Overvalued on GF Value™ - GuruFocus
0.86%
0.31%
자본화:
|
볼륨(24시간):